ANI Pharmaceuticals Files 8-K on Financials

Ticker: ANIP · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1023024

Ani Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyAni Pharmaceuticals Inc (ANIP)
Form Type8-K
Filed DateSep 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

TL;DR

ANI Pharma dropped an 8-K on Sept 8th covering financials. Details TBD.

AI Summary

On September 8, 2025, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This filing indicates that ANI Pharmaceuticals is providing updates on its financial performance and operational status to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial information and does not contain any immediately alarming or negative news.

Key Players & Entities

  • ANI PHARMACEUTICALS INC (company) — Registrant
  • 210 MAIN STREET WEST (location) — Principal Executive Offices Address
  • BAUDETTE (location) — City of Principal Executive Offices
  • MINNESOTA (location) — State of Principal Executive Offices
  • 56623 (location) — Zip Code of Principal Executive Offices
  • 2186343500 (phone_number) — Registrant's telephone number
  • BIOSANTE PHARMACEUTICALS INC (company) — Former Company Name
  • BEN ABRAHAM TECHNOLOGIES INC (company) — Former Company Name

FAQ

What specific financial results are being reported in this 8-K filing?

The provided excerpt states the filing concerns 'Results of Operations and Financial Condition' but does not detail the specific financial results.

What is the exact date of the earliest event reported in this 8-K?

The date of the earliest event reported is September 8, 2025.

What is ANI Pharmaceuticals, Inc.'s primary business classification according to the filing?

ANI Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

What was ANI Pharmaceuticals, Inc. previously known as?

ANI Pharmaceuticals, Inc. was formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.

What is the Commission File Number for ANI Pharmaceuticals, Inc.?

The Commission File Number for ANI Pharmaceuticals, Inc. is 001-31812.

Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-08 06:57:45

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., along with members of the Company's executive leadership team, will present at the H.C. Wainwright 27 th Annual Global Investment Conference on September 8, 2025, and at the Morgan Stanley 23 rd Annual Global Healthcare Conference on September 9, 2025, in New York City, and is providing an updated investor presentation. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

01

Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Investor Presentation, dated September 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 8, 2025 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.